探索基于远程策略的远程干预对患有多发性硬化症,日常记忆障碍的人的有效性:试点研究
Yael Goverover1, Saumya Sharan2, Lauren Krupp3
1Yael Goverover, PhD, OTR/L, FAOTA, is Professor, Department of Occupational Therapy, New York University, New York, NY; yg243@nyu.edu.
概括
这项研究表明,一种名为TELE-Self-GEN的远程基于策略的干预措施改善了多发性硬化症 (MS) 患者的记忆力和日常功能. 这些发现支持对这种方便的虚拟认知康复方法进行进一步的试验.
科学领域:
- 神经康复疗法 神经康复疗法
- 认知心理学 认知心理学
- 职业疗法 职业疗法 职业疗法
背景情况:
- 多发性硬化症 (MS) 患者经常经历认知障碍,特别是在日常记忆中.
- 现有的认知康复策略可能无法完全获得或适应MS患者的需求.
- 远程干预提供了一种潜在的解决方案,可以改善MS患者获得护理的机会.
研究的目的:
- 评估基于策略的远程干预 (TELE-Self-GEN) 对MS的记忆障碍的可行性和有效性.
- 评估参与者的满意度和认知康复的虚拟交付方法的便利性.
- 确定TELE-Self-GEN是否可以改善MS患者的记忆性能和功能能力.
主要方法:
- 采用了测试前测试后试点研究设计.
- 十名被诊断患有多发性硬化症的成年人参与了这项研究.
- 一个为期六个会议的在线干预 (TELE-Self-GEN) 将自我生成的学习策略纳入了超认知框架,通过Zoom提供.
主要成果:
- 参与者对虚拟干预表示高度满意,并将便利性列为重大优势.
- TELE-Self-GEN干预导致了可测量的记忆性能改善.
- 参与者在日常生活中表现出增强的感知记忆能力,并在干预后改善功能表现.
结论:
- 本试点研究为远程交付的基于战略的干预提供了初步概念验证,以提高MS的记忆和功能.
- 该TELE-Self-GEN干预表明承诺作为一个可行的和有效的方法,在这一群体的认知康复.
- 结果支持启动一项更大的随机临床试验,以进一步验证TELE-Self-GEN对MS患者的疗效.
相关概念视频
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...
Hebbian LTP
LTP can occur when presynaptic neurons...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...


